Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00033514
Status:
COMPLETED
Last Update Posted:
2020-10-08
First Post:
2002-04-09
Brief Title:
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2Neu Overexpression
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Organization Data
Organization:
Jonsson Comprehensive Cancer Center
Class:
OTHER
Study ID:
01-06-020
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |